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Summary
Lymphotoxin-mediated activation of the lymphotoxin-b receptor (LTbR;
LTBR) has been implicated in cancer, but its role in T-cell acute lym-
phoblastic leukaemia (T-ALL) has remained elusive. Here we show that the
genes encoding lymphotoxin (LT)-a and LTb (LTA, LTB) are expressed in
T-ALL patient samples, mostly of the TAL/LMO molecular subtype, and in
the TEL-JAK2 transgenic mouse model of cortical/mature T-ALL (Lta,
Ltb). In these mice, expression of Lta and Ltb is elevated in early stage T-
ALL. Surface LTa1b2 protein is expressed in primary mouse T-ALL cells,
but only in the absence of microenvironmental LTbR interaction. Indeed,
surface LT expression is suppressed in leukaemic cells contacting Ltbr-ex-
pressing but not Ltbr-deficient stromal cells, both in vitro and in vivo, thus
indicating that dynamic surface LT expression in leukaemic cells depends
on interaction with its receptor. Supporting the notion that LT signalling
plays a role in T-ALL, inactivation of Ltbr results in a significant delay in
TEL-JAK2-induced leukaemia onset. Moreover, young asymptomatic TEL-
JAK2;Ltbr/ mice present markedly less leukaemic thymocytes than age-
matched TEL-JAK2;Ltbr+/+ mice and interference with LTbR function at
this early stage delayed T-ALL development. We conclude that LT expres-
sion by T-ALL cells activates LTbR signalling in thymic stromal cells, thus
promoting leukaemogenesis.
Keywords: lymphotoxin, lymphotoxin-beta receptor, T-cell acute lym-
phoblastic leukaemia, tumour microenvironment, tumour-stromal interac-
tions.
T-cell acute lymphoblastic leukaemia (T-ALL) is an aggres-
sive malignancy of thymocytes that affects mainly children
and adolescents, is fatal without therapy, and is characterized
by a number of cell-autonomous genetic and molecular alter-
ations (Graux et al, 2006; Van Vlierberghe & Ferrando,
2012). Several cell-extrinsic factors involved in T-ALL have
been studied in vitro or in vivo, including growth factors
[e.g. interleukin 7 (IL7), IL18 and insulin-like growth factor
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1 (IGF1)], chemokines, Notch ligands (DLL4) and adhesion
molecules (e.g. ICAM1) (Winter et al, 2001; Buonamici et al,
2009; Medyouf et al, 2011; Silva et al, 2011; Mirandola et al,
2012; Uzan et al, 2014; Minuzzo et al, 2015). Furthermore,
our group has found that expression of the NF-jB transcrip-
tion factor RELB in non-haematopoietic stromal cells con-
tributes to the development of T-ALL in a mouse model
(dos Santos et al, 2008). RELB is a critical NF-jB transcrip-
tion factor that is activated following engagement of tumour
necrosis factor receptor (TNFR) superfamily members, thus
hinting that TNFR-like signalling is implicated in T-ALL
(dos Santos et al, 2010).
The lymphotoxin-beta receptor (LTbR; LTBR) is a mem-
ber of the TNFR superfamily that is activated by either of
two ligands, the lymphotoxin (LT) heterotrimer LTa1b2 or
LIGHT/TNFSF14 homotrimer (Ware, 2005; Remouchamps
et al, 2011). Expression of LTa1b2 is found at the surface of
activated T, B and NK cells (Ware et al, 1992; Browning
et al, 1993), while LIGHT protein is mainly expressed on
activated T cells (Mauri et al, 1998). The LTbR receptor is
constitutively expressed in stromal cells (e.g. fibroblasts,
epithelial cells, and endothelial cells) of primary and sec-
ondary lymphoid organs and in myeloid lineage cells, but
not expressed in T or B lymphocytes (Force et al, 1995; Mur-
phy et al, 1998). LTbR activates both canonical and non-
canonical NF-jB signalling pathways (Dejardin et al, 2002;
Ganeff et al, 2011), thus inducing specific transcriptional
programmes that include the expression of chemokines (e.g.
CXCL13, CCL21 and CCL19) and adhesion molecules
(ICAM1, VCAM1 and MAdCAM1) (Dejardin et al, 2002;
Ganeff et al, 2011; Benezech et al, 2012). Knock-out mouse
models inactivating LTbR or downstream signalling proteins
showed that this pathway is essential for the development of
secondary lymphoid organs, and for the generation and
maintenance of splenic and thymic microarchitecture (Re-
mouchamps et al, 2011). In the thymus, the LTa1b2-LTbR
signalling axis is involved not only in the development and
maintenance of the stromal cell network, but also in thymo-
cyte development, which requires reciprocal interactions
between thymocytes and stromal cells either by direct cell-to-
cell contact or by soluble factor production (F€utterer et al,
1998; Klug et al, 1998; Boehm et al, 2003; Ware, 2005).
Despite early evidence for anti-tumour properties of the
LTbR signalling pathway, several reports pinpointed a pro-
oncogenic role for LT signalling in both solid and haemato-
logical malignancies (Wolf et al, 2010). In some settings,
LTbR signalling is expressed in malignant cells and is acti-
vated by LT-expressing lymphocytes present in the tumour
microenvironment (Haybaeck et al, 2009; Ammirante et al,
2010), while in others LTbR is expressed in specific tumour
microenvironmental cells and is activated by either cancer or
other stromal cells expressing LT (Rehm et al, 2011; Lau
et al, 2014). mRNA and protein expression of LT has long
been reported in T-ALL cell lines (Sung et al, 1988; Ware
et al, 1992), but the expression in primary T-ALL as well as
its physiological relevance in disease development has not yet
been addressed.
Here, we report that T-ALL patient samples express the
LTA and LTB genes, this expression being more pronounced
in the TAL/LMO molecular subtype. Using the TEL-JAK2
transgenic mouse model of cortical/mature T-ALL, we docu-
ment that the LTa1b2 ligand is expressed at the surface of
TEL-JAK2 leukaemic cells and that LTbR genetic inactivation
leads to a significant delay in T-ALL development.
Materials and methods
Mice
ElSRa-TEL-JAK2 transgenic (TJ2-Tg) mice (Carron et al,
2000) were bred with Ltbr knockout mice (F€utterer et al,
1998), provided by Dr. Jorge Caama~no (University of Birm-
ingham, Birmingham, UK), all on the C57BL/6 background.
Mice were maintained in the specific pathogen-free CBMR/
UAlg Animal Facility (Faro, Portugal) and the experimental
procedures followed recommendations for the care and use
of laboratory animals from the European Commission
(Directive 2010/63/UE) and Portuguese authorities (Decreto-
Lei n113/2013). TJ2-Tg and recipient mice were monitored
for leukaemia development and killed by CO2 inhalation
when manifesting signs of disease (i.e. dyspnoea, lethargy,
enlarged lymph nodes or enlarged abdomen). For LT in vivo
inhibition, TJ2-Tg mice were intraperitoneally injected with
100 lg of muLTbR-muIgG fusion protein (provided by Bio-
gen Idec, Cambridge, MA, USA) or control ChromPure
mouse IgG (Jackson Immunoresearch Laboratories, West
Grove, PA, USA) for five consecutive weeks, starting at
5 weeks of age. For detection of malignant thymocytes in
early stage T-ALL, TJ2-Tg mice were killed at 8 weeks of age,
and the percentage of CD8+CD25+ cells in thymocyte sus-
pensions was determined.
Human T-ALL and thymocyte samples
Primary T-ALL samples were obtained at diagnosis from
bone marrow and/or peripheral blood with high leukaemia
involvement (>85%), and enriched by density centrifugation
over Ficoll-Paque (GE Healthcare, Little Chalfont, UK).
Microarray analyses were performed on samples from 51
paediatric patients with newly diagnosed T-ALL accrued
from 2000 to 2013 at Centro Infantil Boldrini, Campinas,
Brazil. Most patients (n = 44) were treated according to the
Brazilian GBTLI-99 Childhood ALL Treatment protocol
(Brandalise et al, 2010). The use of patient samples was
approved by the FCM/UNICAMP Research Ethics Commit-
tee (CAAE: 0014.0.144.146-08) and informed consent was
obtained from parents. Thymic samples, obtained from chil-
dren undergoing cardiac surgery, were gently minced in cul-
ture medium and subsequently subjected to density
centrifugation. Informed consent and Institutional Review
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Board approval were obtained for all sample collections in
accordance with the Declaration of Helsinki.
Microarray data sets and data analysis
Microarray data sets were obtained from the publicly avail-
able Gene Expression Omnibus database, including gene
expression data from the Microarray Innovations In Leukae-
mia (MILE) study (GSE 13159) to evaluate the expression of
LTA and LTB in subtypes of leukaemia compared to non-
leukaemia and healthy bone marrow samples (Haferlach
et al, 2010). To compare the expression profile of TJ2-Tg
mouse T-ALL with that of different stages of mouse thymo-
cyte differentiation, we obtained thymocyte gene expression
data from the Immunological Genome Project (Heng &
Painter, 2008) and expression data from TJ2-Tg leukaemic
cells (Waibel et al, 2013) (GSE15907 and GSE51243, respec-
tively). All datasets were pre-processed using Robust Multi-
array Average as implemented in the R/Bioconductor
environment (Gentleman et al, 2004). The log2 signal intensi-
ties of the annotated genes were obtained and the co-efficient
variation for each gene was computed. We thus obtained the
top 1% (n = 163) of genes that showed least co-efficient of
variation. Further, we performed hierarchical clustering of
samples using the complete linkage analysis method imple-
mented in the TM4 software on the above mentioned mouse
datasets. In addition to the clustering analysis we performed
functional enrichment analysis of the 163-gene dataset using
Gene Set Enrichment Analysis (GSEA) to identify enriched
biological processes, molecular functions and pathways
(Subramanian et al, 2005). The statistical significance of
enrichment was estimated and all the functional categories
and pathways with a false discovery rate of ≤005 were
considered.
Gene expression microarray analysis of T-ALL patient
samples
Total RNA was extracted from 51 paediatric T-ALL samples
preserved in guanidine isothiocyanate solution using the
Illustra RNAspin Mini RNA Isolation Kit (GE Healthcare).
Total RNA from two human thymocyte samples was
extracted with Trizol (Life Technologies, Carlsbad, CA,
USA). RNA samples were processed with the WT Expression
Kit (Ambion, Austin, TX, USA) and GeneChip WT Terminal
Labeling and Controls Kit (Affymetrix, Santa Clara, CA,
USA), and hybridized on Human Gene 1.0 ST Arrays (Affy-
metrix). Array files are publicly available through the Gene
Expression Omnibus (GEO) database under the accession
numbers GSE50999 and GSE66638. Expression values were
obtained with the iterPLIER+16 algorithm in the Affymetrix
Expression Console, and transformed to Z-score to a log2
scale. Molecular subtypes were classified by hierarchical clus-
tering analysis (Pearson correlation and pairwise average-
linkage; http://genepattern.broadinstitute.org/) according to
the expression of genes previously associated with each sub-
type (Homminga et al, 2011). We used the Affymetrix Com-
plex Match table to identify those probe sets in the original
Human Genome U133 Plus 2.0 Array (Homminga et al,
2011) that were most related to probe sets available in the
Human Gene 1.0 ST Array. Two out of the 51 T-ALL sam-
ples could not be classified and thus were excluded from
analysis.
Human cell lines
T-ALL cell lines DND41, PF382, P12 and SUPT1 were pro-
vided by Dr. Hind Medyouf and Dr. Andrew P. Weng (BC
Cancer Agency, Vancouver, Canada). Jurkat and Nalm6 cell
lines were available in-house (Barata et al, 2006). Leukaemic
cell lines were cultured in complete RPMI medium (Lonza,
Basel, Switzerland) supplemented with 10% heat-inactivated
foetal bovine serum (PAA Laboratories, Linz, Austria),
2 mmol/l L-glutamine, 100 U/ml of penicillin and 100 lg/ml
of streptomycin (Lonza) and maintained at 37°C under a
humidified atmosphere with 5% CO2. Cell lines were cul-
tured at 1 9 106 cells/ml and treated for 10 h with either
dimethyl sulfoxide (DMSO; control), 50 ng/ml phorbol 12-
myristate 13-acetate (PMA) (Sigma-Aldrich, St. Louis, MO,
USA) and/or 10 lmol/l BMS-345541 (IKKi) (Calbiochem,
Billerica, MA, USA) for both mRNA and cell surface protein
detection.
Reverse transcription quantitative PCR (RT-qPCR)
Total RNA from mouse cells and cell lines was prepared
using Trizol reagent (Life Technologies) and Direct-zol RNA
miniprep (Zymo Research, Irvine, CA, USA), following the
manufacturer0s instructions. RNA samples were treated with
DNase I (Thermo Fisher Scientific, Waltham, MA, USA) to
remove remaining genomic DNA. Then, total RNA (1 lg)
was reverse-transcribed using the First Strand cDNA Synthe-
sis Kit (Thermo Fisher Scientific) and oligo(dT)18 primers.
Quantitative PCR reactions, containing 2 ll of 1:20 diluted
cDNA in 20 ll, SsoFast EvaGreen Supermix (Bio-Rad, Her-
cules, CA, USA) and 300 nmol/l of murine or human gene-
specific primers (see Table SI) were performed on a C1000
Thermal Cycler coupled to a CFX 96 Real-time PCR detec-
tion system (Bio-Rad). PCR results were analysed by Bio-Rad
CFX Manager software, version 3.0, treated using the com-
parative CT method (2
ΔΔC(T) method), and the mean fold
change in expression of the target gene was calculated in
relation to reference gene expression (Gapdh for murine
samples and GAPDH or RNA18S5 rRNA for human sam-
ples). For quantification of LTA and LTB expression in the
molecular subgroups of T-ALL, total RNA (1 lg) was reverse
transcribed using the ImProm II Reverse Transcriptase
enzyme (Promega, Madison, WI, USA) and random hexam-
ers (25 lmol/l). PCR reactions were carried out in 15 ll
containing 5 ll of 1:25 diluted cDNA, 75 ll Maxima Probe/
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ROX qPCR Master Mix (Thermo Fisher Scientific),
300 nmol/l of each primer and 200 nmol/l of TaqMan probe
(sequences listed in Table SI). Amplification reactions were
performed in a 7500 Fast Real-Time PCR System (Life Tech-
nologies). Expression values of LTA and LTB were calculated
by the 2ΔΔC(T) method using ABL1 as endogenous normal-
izer and Jurkat cells as calibrator. Efficiencies for both the
normalizer and target genes were 100% 10%.
Primary murine leukaemic T cell isolation and ex vivo
culture
Primary TJ2-Tg leukaemic cells were obtained as single cell
suspensions from the thymus or spleen, after gentle dissocia-
tion and filtration through 70 lm nylon cell strainers. Bone
marrow single cell suspensions were obtained by flushing
phosphate-buffered saline (PBS) through tibiae and femora.
For molecular analyses, primary cells were cultured in com-
plete RPMI medium at 2 9 106 cells/ml and treated with
either DMSO (control), 1 lg/ml actinomycin D (ActD),
50 lg/ml cycloheximide (CHX), 10 ng/ml PMA and 250 ng/
ml ionomycin (PMA+Iono) (all from Sigma-Aldrich),
10 lmol/l Tetracyclic Pyridone 6 (InSolution Jak Inhibitor I,
JAKi) or 10 lmol/l BMS-345541 (IKKi) (both from Cal-
biochem), as indicated.
Co-cultures
Ltbr+/ and Ltbr/ mouse embryonic fibroblasts (MEFs)
were prepared by standard procedures. MEFs and the MS5
murine bone marrow stromal cell line, provided by Dr.
Francoise Pflumio (CEA, Fontenay-aux-Roses, France), were
maintained in Dulbecco’s modified Eagle medium (DMEM;
Lonza) or a minimal essential medium (aMEM, Gibco,
Grand Island, NY, USA), respectively, and supplemented
with 10% FBS (PAA), 2 mmol/l L-glutamine, antibiotics, and
01 mmol/l 2-mercaptoethanol (Gibco). TJ2-Tg leukaemic
cells (1 9 106 cells/ml) were co-cultured in triplicate with
confluent MS5 cells or MEFs in complete RPMI medium.
Co-cultured leukaemic cells in suspension (non-adherent)
were collected for flow cytometry analysis. The remaining
culture was washed twice with PBS and then incubated with
enzyme-free cell dissociation buffer (Gibco) at 37°C. Dissoci-
ated leukaemic cells (adherent) were discriminated from MS5
or MEFs through flow cytometry detection of the Thy1.2
T-cell surface marker.
Flow cytometry and cell sorting
Single-cell suspensions were stained with fluorochrome-la-
belled antibodies and detected in a FACS Calibur flow
cytometer (BD Biosciences, San Jose, CA, USA) or sorted
using a FACSAria I (BD Biosciences), as indicated. Fluores-
cein isothiocyanate (FITC)-, R-phycoerythrin (PE)-, PE-cya-
nin 5 (PE-Cy5)-, or allophycocyanin (APC)-conjugated
antibodies specific for CD3e (145-2C11), CD25 (PC61),
CD69 (H1.2F3), CD4 (GK1.5), CD8 (53-6.7), CD24 (M1/
69), CD44 (IM7) and Thy1.2 (30-H12) (BioLegend, San
Diego, CA USA) were used. Membrane-bound LTbR ligands
were detected using the muLTbR-huIgG (LTbR-Fc) fusion
protein, as previously described (Ansel et al, 2000). Intracel-
lular LTb was detected in paraformaldehyde-fixed saponin-
permeabilized cells using a hamster anti-mouse LTb
(BBF6.BF12) monoclonal antibody (Browning et al, 1997).
The LTbR-Fc fusion protein (and human IgG negative con-
trol) and the hamster anti-mouse LTb (and anti-KLH
Armenian hamster Ig Ha4/8 negative control), all kindly
provided by Dr. Jeffrey L. Browning (Biogen Idec and Bos-
ton University School of Medicine), were visualized using
PE-conjugated AffiniPure F(ab’)2 fragment donkey anti-hu-
man IgG (H+L) (Jackson ImmunoResearch Laboratories)
and FITC-conjugated goat anti-hamster (Armenian) IgG
(BioLegend) secondary antibodies, respectively. Nonviable
cells were excluded from analyses by propidium iodide
(Sigma-Aldrich) or 7-AAD (BioLegend) staining and appro-
priate gating. The data were analysed on CellQuest (BD
Biosciences) software.
Statistics
Statistical analyses were performed using Prism 5 (GraphPad
Software, La Jolla CA, USA). Statistical tests were used as indi-
cated in figure legends. Kaplan–Meier survival curves were
plotted and P values were calculated using the log-rank Mantel
Cox test. A P < 005 was considered statistically significant.
Results
Lymphotoxin gene expression in T-ALL patient cells
Initial analysis of LTA and LTB transcripts and cell surface
LT protein showed heterogeneous but detectable expression
in several human T-ALL cell lines, but not in the Nalm6
B-cell precursor leukaemia cell line (Fig 1A, B). LTA and
LTB mRNA and surface LT expression was upregulated by
phorbol ester treatment and blocked by an IKK inhibitor in
all T-ALL cell lines tested (Fig 1C–E). Together, these data
confirmed previous reports obtained with other T-ALL cell
lines (Sung et al, 1988; Ware et al, 1992) indicating that the
LT genes and LTa1b2 heterotrimers are expressed in human
T-ALL cells in an NF-jB-dependent manner.
Analysis of a publically available large multicentre dataset
of 2022 leukaemia patient and 74 non-malignant bone mar-
row (BM) samples (Haferlach et al, 2010) showed that LTA
and LTB genes were significantly more expressed in T-ALL
and other lymphoid malignancies than in myeloid malignan-
cies or non-malignant BM (Fig 2A). Human thymocytes
express LT (Wolf & Cohen, 1992), so we evaluated LTA and
LTB expression in T-ALL paediatric patient samples
(Table SII) as compared to age-matched human thymocytes.
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Fig 2. T-ALL patient samples express lymphotoxin genes. (A) Microarray (GEO GSE 13159) analysis of LTA and LTB gene expression levels in several
human samples: B-ALL, B-cell acute lymphoblastic leukaemia (n = 576); T-ALL, T-cell acute lymphoblastic leukaemia (n = 174); CLL, chronic lym-
phocytic leukaemia (n = 448); AML, acute myeloid leukaemia (n = 542); CML, chronic myeloid leukaemia (n = 76); MDS, myelodysplastic syn-
drome (n = 206); Non-leukaemia, non-leukaemia and healthy bone marrow samples (n = 74). Lines, bars and whiskers represent the median,
quartiles and minimum and maximum values, respectively. P values were calculated by pairwise comparisons between B-ALL and T-ALL, and T-ALL
and AML using the two-tailed unpaired Student’s t test with or without Welch0s correction to account for unequal variances when appropriate. See
Table SV for further pairwise comparisons. (B) RT-qPCR quantification of LTA and LTB mRNA levels in human thymocytes (n = 7) and T-ALL
patient samples (n = 8) (relative to RNA18S5 rRNA expression); mean of technical triplicates for each sample. (C) LTA and LTB gene expression, as
determined by microarray analysis, in 49 T-ALL samples, classified according to molecular subtype [HOXA (n = 5), immature (n = 4), proliferative
(n = 5), TLX (n = 12) and TAL/LMO (n = 23)], and 2 human thymocyte samples (bar represents mean expression). P values were calculated by com-
paring TAL/LMO and the other molecular subtypes combined (i.e. HOXA, immature, proliferative and TLX) using the two-tailed unpaired Student’s
t test. (D) RT-qPCR quantification of LTA and LTB (relative to ABL1 expression and calibrated to expression in Jurkat cells) in 33 T-ALL patient sam-
ples classified according to molecular subtype [HOXA (n = 3), immature (n = 4), proliferative (n = 4), TLX (n = 8) and TAL/LMO (n = 14)]. P val-
ues were calculated by comparison between TAL/LMO and the other molecular subtypes combined (i.e. HOXA, immature, proliferative and TLX)
using the two-tailed unpaired Student’s t test alone or with Welch0s correction to account for unequal variances when appropriate.
Fig 1. T-cell acute lymphoblastic leukaemia (T-ALL) patient cell lines express lymphotoxin proteins in an NF-jB-dependent manner. (A) RT-
qPCR quantification of LTA and LTB mRNA levels (relative to GAPDH expression) in the indicated cell lines (mean  range of technical tripli-
cates of one representative analysis of at least 2 performed for each cell line). (B) Cell surface immunostaining with LTbR-Fc (solid line) or
secondary antibody alone (grey shading) on the indicated T-ALL cell lines and Nalm6 B-cell line. (C) RT-qPCR quantification of LTA and LTB
(relative to GAPDH expression) in DND41, PF382, SUPT1 and Nalm6 cell lines treated for 10 h with either IKK inhibitor (IKKi), phorbol 12-
myristate 13-acetate (PMA) or dimethyl sulfoxide (DMSO) (mean  range of technical triplicates). (D) Statistical analyses of combined RT-qPCR
data from three T-ALL cell line biological replicates (DND41, PF382, and SUPT1). P values determined by paired t-tests are indicated. (E) LTbR-
Fc immunostaining of indicated cell lines treated for 10 h with PMA, PMA plus IKKi, or DMSO.
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By doing so, we found LTA and LTB expression in normal
thymocytes and T-ALL samples, albeit heterogeneously in the
latter, some expressing levels that were higher, while others
were lower than those found in thymocytes (Fig 2B). To
determine whether LT gene expression was associated with
particular molecular or oncogenic subgroups (Graux et al,
2006), we assessed LTA and LTB expression in a larger
cohort of 49 primary T-ALL patients by microarray analysis
followed by RT-qPCR validation in a subset of 33 patients
(see Table SIII for the immunophenotypic and genetic char-
acteristics of T-ALL diagnostic samples). Molecular subtypes
were classified by hierarchical clustering analysis (HCA)
according to the expression of genes previously associated
with each subtype (Homminga et al, 2011). The LTA and
LTB genes were expressed at variable levels in the different
molecular subtypes, but expression of LTA and LTB was sig-
nificantly higher in the TAL/LMO molecular subgroup than
in the remaining samples (Fig 1C). RT-qPCR analyses cor-
roborated that LTA and LTB were expressed at higher levels
in the TAL/LMO T-ALL subgroup than in immature T-ALL
(Fig 1D and Table SIII). Together, these data indicate that
higher LT expression is associated with a particular subset of
T-ALL patients.
LT expression in a mouse model of cortical/mature T-
ALL
The TAL/LMO molecular subtype of T-ALL has been associ-
ated with ab T-cell receptor (TCR) lineage differentiation,
cell surface expression of abTCR and CD3, and cortical/ma-
ture immunophenotype (Ferrando et al, 2002; Asnafi et al,
2004; Soulier et al, 2005; Graux et al, 2006). Moreover, TAL/
LMO samples were reported to cluster preferentially with
post-b-selection human thymocyte subsets, including imma-
ture CD4 single-positive (SP), CD4/CD8 double-positive
(DP), and mature CD4 and CD8 SP cells (Soulier et al,
2005). To study the role of LT in T-ALL development, we
used TEL-JAK2 transgenic mice (TJ2-Tg), a model of corti-
cal/mature T-ALL that is characterized by the presence of
CD4/CD8 DP and CD8 SP leukaemic cells, expression of sur-
face abTCR, CD3 and CD5, and responsiveness to TCR
stimulation (Carron et al, 2000; dos Santos et al, 2007). Fur-
thermore, unsupervised clustering analysis of four TJ2-Tg
leukaemic samples and nine thymocyte subpopulations,
based on the expression levels of 163 highly variable genes,
revealed that the latter clustered with double negative stage 4
(DN4), CD8 ISP and DP thymocytes (Fig S1 and Table SIV).
These results indicate that TJ2-Tg mouse leukaemias, like
most TAL/LMO T-ALL cases, are malignancies of late corti-
cal, post-b-selection thymocytes. We first assessed Lta and
Ltb expression in primary TJ2-Tg leukaemic cells from dis-
eased mice, and found these genes to be expressed on aver-
age at four- to five-fold higher levels than wild-type
thymocytes (Fig 3A). Additionally, Lta and Ltb expression
was higher in TJ2-Tg leukaemic cells than in sorted CD4 SP
thymocytes, which are one of the main sources of LTbR
ligands in the adult thymus (Fig 3B) (Boehm et al, 2003;
Hikosaka et al, 2008). These results show that, similarly to
human T-ALL samples, murine TEL-JAK2 leukaemic cells
present high LT expression.
To study how LT expression is regulated in TJ2-Tg leukae-
mic cells, we inhibited the JAK/STAT and IKK/NF-jB sig-
nalling pathways, which were reported to be activated in
these cells (Carron et al, 2000; dos Santos et al, 2008) and to
induce Lta and Ltb expression in T lymphocytes (She-
bzukhov & Kuprash, 2011). Treatment of leukaemic cells
with a pan-JAK inhibitor downregulated Lta (and the control
Socs2 gene) but not Ltb mRNA expression (Fig 3C). Similarly
to human T-ALL cell lines, mouse leukaemic cell treatment
with an IKK kinase inhibitor markedly downregulated both
Lta and Ltb mRNAs (and the control Nfkb2 gene) (Fig 3D).
As expected, the IKK inhibitor blocked Lta and Ltb induction
by PMA/ionomycin in TJ2-Tg leukaemic cells (Fig S2). It is
worth noting that short treatment with these inhibitors did
not induce significant leukaemic cell death (data not shown).
Together, these experiments indicate that JAK and IKK
kinases are key regulators of lymphotoxin gene expression in
human and mouse T-ALL cells.
In thymocytes, NF-jB transcription factors are activated
by pre-TCR and abTCR signalling (Moore et al, 1995;
Aifantis et al, 2001). Given that Lta and Ltb expression is
induced by TCR during TCR-mediated thymocyte positive
selection (Irla et al, 2012), we reasoned that the pre-TCR
or TCR could regulate LT gene expression in leukaemic
cells. Quantification of Lta and Ltb mRNAs in TJ2-Tg;
Rag2/ leukaemic cells, which are pre-TCR and TCR-defi-
cient (dos Santos et al, 2007), showed that Ltb, but not
Lta expression was decreased, as compared to pre-TCR/
TCR-proficient TJ2-Tg leukaemic cells (Fig 3E). These data
indicate that TCR signalling induces Ltb gene expression in
T-ALL cells.
LTa1b2 heterotrimer surface expression on TEL-JAK2
T-ALL cells is downmodulated in vivo and depends on
de novo protein synthesis
To detect LT surface protein on TJ2-Tg cells, we first treated
cells with PMA and ionomycin. Consistent with mRNA
expression results, we detected membrane-bound LTbR
ligands at higher levels in TJ2-Tg leukaemic cells than in
wild-type thymocytes (Fig S3). However, in untreated leukae-
mic cells, LT protein was detected only upon cell permeabi-
lization (Fig 4A). Interestingly, upon ex vivo culture, primary
leukaemic cells showed LTbR-Fc staining, peaking at around
24 h (Figs 4A, B and S4). Anti-LTb monoclonal antibody
(mAb) pre-incubation blocked completely the cell surface
LTbR-Fc signal in ex vivo-cultured and in PMA/ionomycin-
treated cells, indicating that only LTa1b2 heterotrimers but
not LIGHT were expressed at the cell surface (Figs 4A and
S5A). Collectively, these results indicate that ex vivo-cultured
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or PMA/ionomycin-stimulated TJ2-Tg leukaemic cells
express surface LTa1b2 heterotrimers.
The observed LT cell surface expression following ex vivo
culture and PMA/ionomycin stimulation of mouse leukaemic
cells could result from a combination of de novo protein syn-
thesis and protein subcellular relocalization. To assess the
role of de novo protein synthesis, we blocked transcription
and translation by treating TJ2-Tg leukaemic cells with acti-
nomycin D or cycloheximide, respectively. Both compounds
blocked LTa1b2 cell surface induction upon either ex vivo
culture or PMA/ionomycin stimulation (Fig S5A, B), indicat-
ing that sustained LTa1b2 surface expression in leukaemic
cells depends on de novo mRNA and protein synthesis in
both conditions. To verify whether ex vivo culturing also
induced Lta and Ltb mRNA, we performed RT-qPCR analy-
sis in leukaemic cells freshly collected or cultured ex vivo.
Ltb, but not Lta mRNA expression increased following
ex vivo culture (Fig S5C). Together, these results indicate that
LTa1b2 expression at the surface of ex vivo-cultured and
stimulated leukaemic cells depends on LT gene transcription
and continuous protein synthesis.
Microenvironmental LTbR downmodulates cell surface
LT expression on TEL-JAK2 leukaemic T cells
Given that surface LT expression was detected on primary
leukaemic cells only upon ex vivo culture, we sought to
determine whether lack of LT expression in vivo depended
upon interaction with LTbR expressed by stromal cells. To
this end, we inoculated TJ2-Tg leukaemic cells in Ltbr+/
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and Ltbr/ mice and collected expanded cells for analysis 3–
4 weeks later. Similarly to spontaneously generated leukaemic
cells (Fig 4), leukaemic cells collected from Ltbr-proficient
mouse organs (gated on CD8+CD25+ cells) did not display
detectable LTa1b2 surface expression (Fig 5A). In contrast
and strikingly, LTa1b2 surface expression was markedly sus-
tained in leukaemic cells collected from different tissues (thy-
mus, spleen, bone marrow and peripheral blood) of Ltbr/
recipient mice (Figs 5A, B and S6). Similar results were
obtained upon inoculation of TJ2-Tg;Ltbr/ leukaemic cells
in Ltbr+/ and Ltbr/ mice (data not shown). These results
indicate that LTa1b2 expression on the TJ2-Tg leukaemic cell
surface is downmodulated when these cells are localized within
LTbR-expressing tissue microenvironments.
To investigate whether downmodulation of LTa1b2 surface
expression depends on direct cell contact, we co-cultured
TJ2-Tg leukaemic cells with stromal cell lines. The bone mar-
row-derived MS5 stromal cell line, which expresses surface
LTbR (Fig S7), was shown to sustain the survival of co-cul-
tured TJ2-Tg leukaemic cells (Fig 5C). Upon co-culture, leu-
kaemic cells adhering to the MS5 monolayer showed lower
levels of surface LTa1b2 than either non-adhering co-cultured
leukaemic cells or leukaemic cells cultured in absence of MS5
cells (Fig 5D, E). Conditioned medium collected from co-
cultured leukaemic cells with MS5 cells did not impair
LTa1b2 upregulation in leukaemic cells cultured in the
absence of MS5 cells (Fig S8), indicating that soluble factors
produced in co-cultures are not sufficient for LTa1b2 down-
modulation. To determine whether interaction with LTbR
was required for LTa1b2 downmodulation, TJ2-Tg leukaemic
cells were co-cultured with either Ltbr/ or Ltbr+/ mouse
embryonic fibroblasts (MEFs). Strikingly, Ltbr-deficient, but
not Ltbr-proficient MEFs failed to downmodulate LT from
the surface of adhering leukaemic cells (Fig 5F, G), thus indi-
cating that this phenomenon is mediated by interaction with
LTbR in microenvironmental cells. These results indicate
therefore that direct contact between the leukaemic cell and
LTbR-expressing stromal cells is required for surface LTa1b2
downmodulation. Moreover, we conclude that the increased
levels of leukaemic cell surface LTa1b2 in Ltbr-deficient recip-
ient mice is caused by defective LTbR expression in microen-
vironmental cells, and not by putative indirect cellular or
systemic defects in Ltbr-deficient recipient mice.
LTbR inactivation delays leukaemogenesis in TEL-JAK2
transgenic mice
The above results indicate a potential LTa1b2-LTbR func-
tional interaction between leukaemic and stromal cells. To
investigate whether LTbR activation is involved in T-cell
leukaemogenesis, TJ2-Tg mice were bred with Ltbr knockout
mice. Strikingly, we found that TJ2-Tg;Ltbr/ mice devel-
oped T-ALL with longer latency than TJ2-Tg;Ltbr+/ mice
(median survival of 23 weeks vs. 15 weeks) (Fig 6A). Despite
the observed delay in leukaemogenesis, Ltbr gene inactivation
did not impact on the leukaemic cell surface marker pheno-
type (CD3, CD4, CD8, CD24 and CD25 expression) charac-
teristic of TJ2-Tg mice (dos Santos et al, 2007) (Fig S9), nor
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on endpoint tumour burden in lymphoid and visceral organs
(Fig 6B), except for lymph nodes, which are absent in Ltbr
knockout mice (F€utterer et al, 1998). Similar to leukaemic
cells transplanted to Ltbr/ mice, those collected from Ltbr-
deficient, but not from Ltbr-proficient TJ2-Tg mice expressed
surface LTa1b2 (Fig 6C, D), thus confirming that LTa1b2
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surface expression in both normal and malignant T cells is
only detectable in the absence of the cognate receptor
(Boehm et al, 2003). Of note, the observed delay in leukae-
mogenesis in the absence of LTbR was not linked to putative
T-cell defects, because LTbR-deficient mice aged 19–
22 weeks, an age when most Ltbr-proficient TJ2-Tg mice
have developed terminal disease, presented no major defects
in cellularity and differentiation of thymocytes (Fig S10A–D),
the targets of TJ2-Tg-induced transformation. Furthermore,
inhibition of LT signalling through the administration of
neutralizing LTbR-Fc fusion protein to young pre-leukaemic
TJ2-Tg mice (with intact thymocyte and lymphoid organ dif-
ferentiation) prolonged mouse survival (Fig 6E). Together,
these results indicate that delayed leukaemogenesis in Ltbr-
deficient mice could not be attributed to either T-cell defects
or absence of lymph nodes and, more importantly, that LTbR
signalling in non-malignant microenvironmental cells pro-
motes leukaemogenesis.
LT signalling fosters the early stages of leukaemogenesis
To determine the role of LTbR signalling at early stages of
disease, we analysed young (8-week-old) TJ2-Tg mice with-
out signs of disease for the presence of aberrant CD8+CD25+
cells in organs commonly affected by T-ALL. CD8+CD25+
cells were consistently found, although at variable propor-
tions, in the thymus of asymptomatic mice, but not to same
extent in spleen, bone marrow and blood (Fig S11). Upon
transplantation to nude mice, thymocyte suspensions includ-
ing CD8+CD25+ cells generated secondary leukaemia (data
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not shown). These data confirm that the first malignantly
transformed T cells in the TJ2-Tg mouse model arise in the
thymus.
To investigate whether LT signalling participates in the
early phases of T-ALL, we analysed LT gene expression in
thymocytes from 8-week-old asymptomatic TJ2-Tg mice and
non-transgenic littermates. Interestingly, the increased pro-
portion of CD8+CD25+ malignant thymocytes observed in
young TJ2-Tg mice (without thymic enlargement) was asso-
ciated with increased Lta and Ltb expression (Figs 6F, G and
S12A, B). More specifically, significantly higher levels of Lta
and Ltb expression were found in samples where
CD8+CD25+ cells accounted for more than 5% of thymo-
cytes (Fig S12C). To investigate whether LT signalling pro-
motes leukaemogenesis at the initial steps of disease, we
detected malignant (CD8+CD25+) thymocytes in asymp-
tomatic 8-week-old TJ2-Tg mice of different Ltbr genotypes.
Interestingly, the proportion of malignant thymocytes was
significantly reduced in Ltbr-deficient mice, as compared to
Ltbr-proficient mice (Fig 6H). Together, these data indicate
that increased LT gene expression occurs early in TJ2-Tg-in-
duced leukaemogenesis, and that LTbR signalling at early
stages accelerates disease progression.
Discussion
Although LT expression in T-ALL cell lines has long been
known, the present study disclosed a role for LT expression
in T-ALL development. Indeed, by studying patient samples,
cell lines and a transgenic mouse model, we found that
T-ALL cells express lymphotoxin protein and mRNA, that
leukaemic cell surface LT interacts with LTbR expressed in
stromal cells, and that LTbR expression in thymic microenvi-
ronmental cells promotes T-ALL, especially at the early
stages. LT signalling was shown to be involved in pro-
oncogenic interactions between leukaemic and microenviron-
mental cells in mouse models of B-cell lymphoma and
chronic lymphocytic leukaemia (Rehm et al, 2011; Heinig
et al, 2014). Together with these findings and the observed
elevated LT gene expression in lymphoid malignancies, our
results further reinforce the notion that the
LT-LTbR signalling axis is crucial for lymphoid cell leukae-
mogenesis.
In our study, LT genes were found to be more expressed
in TAL/LMO T-ALL, a subtype associated with the cortical
and mature stages of thymocyte differentiation (Ferrando
et al, 2002; Asnafi et al, 2004; Soulier et al, 2005; Graux et al,
2006). Being considered a thymocyte malignancy, T-ALL is
associated with expression of thymocyte differentiation mark-
ers. As such, LT gene expression in T-ALL may reflect either
the differentiation stage of the cell of origin or the oncogenic
process itself. Regardless of the mechanism involved, the pre-
sented data suggests that, at least in a subset of patients,
T-ALL cells can interact with and modulate LTbR-expressing
microenvironments through LT expression.
In agreement with previous reports (Browning et al,
1997), signalling pathway activation by phorbol ester and
ionophore treatment induced LT gene transcription and sur-
face LTa1b2 expression in both mouse primary T-ALL cells
and human cell lines. By treating TJ2-Tg leukaemic cells and
several T-ALL cell lines with pharmacological inhibitors, we
verified that both basal and PMA/ionomycin-induced LT
expression in mouse and human T-ALL was dependent on
IKK/NF-jB activity, and that Lta expression in TJ2-Tg leu-
kaemic cells was dependent on JAK kinase activity. NF-jB
signalling in T cells can be activated by abTCR or pre-TCR
signalling (Moore et al, 1995; Aifantis et al, 2001; Cheng
et al, 2011). Supporting the notion that these receptor com-
plexes may upregulate LT genes in T-ALL, we observed that
Ltb mRNA levels were reduced in TJ2-Tg leukaemic cells
lacking pre-TCR/abTCR (Rag2-deficient). Thus, our findings
indicate that Ltb gene expression in T-ALL is induced by
TCR or pre-TCR signalling in an NF-jB-dependent manner.
Despite the high levels of Lta and Ltb expression in TJ2-
Tg leukaemic cells, surface LTa1b2 was barely detectable in
cells collected from LTbR-proficient mice, but were readily
detected in leukaemic cells collected from LTbR-deficient
mice, as previously reported for mature T cells (Boehm et al,
2003). These results thus suggest that upon LTbR activation
on stromal cells, the surface levels of LTa1b2 in thymocytes
are downmodulated, possibly due to an autoregulatory
mechanism to dampen LTbR activation. Supporting this
hypothesis, LTa1b2 heterotrimers were found to be upregu-
lated at the leukaemic cell surface upon ex vivo culture in the
absence of stromal cells. Surface LT downmodulation was
directly linked to LTbR expression, as demonstrated by the
detection of surface LT in leukaemic cells in direct contact
with LTbR-deficient MEFs, but not in leukaemic cells in con-
tact with LTbR-expressing MEF or MS5 stromal cells. Fur-
thermore, surface LT downmodulation depended on direct
contact with LTbR-expressing cells, since it was weak in co-
cultured leukaemic cells that did not adhere to stromal cells
and it was not induced by soluble factors from co-culture
conditioned medium. Therefore, these data show that surface
LT downmodulation depends on direct interaction with
LTbR.
Our results indicate that LT signalling occurs in the initial
stages of TEL-JAK2-induced murine T-ALL, which, similar
to TAL/LMO cases in humans, presents features of cortical/
mature T-cell leukaemia. Indeed, increased LT gene expres-
sion was detected in thymocytes from young asymptomatic
TJ2-Tg mice. Furthermore, LTbR deficiency hampered the
initial expansion of T-ALL cells in the thymus. Given that
LTbR is expressed in thymic stromal cells, including epithe-
lial cells and fibroblasts, but not thymocytes (Seach et al,
2008), our findings indicate that emerging LT-expressing leu-
kaemic cells require LTbR-expressing thymic stromal cells for
accelerated disease onset. LTbR-Fc-mediated blockade of
LTbR signalling in pre-leukaemic TJ2-Tg mice indicated that
early interference with this pathway delays leukaemogenesis.
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At the terminal phase of TJ2-Tg-induced T-ALL, we observed
no significant differences in tumour burden, indicating that
at later stages of disease progression, LTbR activation plays a
less prominent role. This suggests that interaction of LT-ex-
pressing leukaemic cells with LTbR-expressing stromal cells
plays a pro-leukaemogenic role when the emerging malignant
cells are in small numbers but not after expansion and con-
sequent reduced contact with the former cells.
The identity of the LTbR-expressing stromal cells and the
mechanisms by which their activation promotes leukaemogen-
esis remain to be elucidated. Given that LTbR is known to
activate the noncanonical NF-jB pathway (Ganeff et al, 2011)
and RelB expression in stromal cells has been implicated in
murine T-ALL (dos Santos et al, 2008), we postulate that
LTa1b2 expression in emerging malignant thymocytes activates
an NF-jB-dependent transcriptional programme in thymic
microenvironmental cells that promotes T-cell leukaemogene-
sis. Cytokines (e.g. BAFF/TNFSF13B) and chemokines (e.g.
CCL5, CCL19, CCL21, CXCL12 and CXCL13) are possibly
involved, because several of these are activated by LTbR in
stromal cells (Dejardin et al, 2002; Seach et al, 2008). Interest-
ingly, expression of CXCR5, the gene encoding the CXCL13
receptor, was found to correlate with LTB expression in our
microarray analysis of T-ALL patients (data not shown), rais-
ing the question of whether CXCL13 induces LT in this dis-
ease. As shown in Fig S1, TJ2-Tg leukemic cells express several
chemokine receptor genes, including Ccr7 and Ccr9. CCL21, a
CCR7 ligand, was found to be highly expressed in TJ2-Tg lym-
phomas (by RT-qPCR and immunohistolgical staining) but
such expression was not affected by LTbR deficiency (data not
shown). In addition, Ccr7 deficiency in TJ2-Tg mice did not
delay leukemogenesis (unpublished data), which indicates that
the role of LTbR in leukemogenesis is not mediated by
CCL19/CCL21/CCR7 signalling. The identity of the LTbR tar-
get proteins, chemokines or others, and whether LTbR-ex-
pressing cells from other organ microenvironments are also
involved in interaction with human or murine T-ALL, merit
further investigation in future studies.
In summary, the identification of molecules mediating
crosstalk between T-ALL and microenvironmental cells is
important to understand how T-ALL arises from thymocytes
and to determine which microenvironmental signals play a
role in the progression, maintenance and chemoresistance of
this malignancy. Several studies have highlighted the role of
stromal factors in T-ALL. Secreted molecules, such as IL7
and IL18, and membrane-bound Notch ligands were shown
to promote T-ALL in vitro proliferation and progression in
xenografted mouse spleen and bone marrow (Silva et al,
2011; Uzan et al, 2014; Minuzzo et al, 2015; Yin et al, 2015).
Moreover, competitive access to growth signals from the thy-
mic microenvironment has been shown to be important for
T-ALL development (Martins et al, 2014). The present work
further demonstrates the importance of the microenviron-
ment in T-ALL and indicates that LT signalling is important
in the early (thymic) stages of this malignancy. Future stud-
ies should address whether LT signalling is involved in later
phases of T-ALL progression and whether it is a potential
therapeutic target in combination with other agents.
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